Manjaro subcutaneous injection 12.5mg Ateos, manufactured by Eli Lilly Japan, contains Tirzepatide. This GIP and GLP-1 receptor agonist is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is provided as a 12.5mg 0.5mL 1 kit with YJ code 2499422G5020.
Manjaro subcutaneous injection 12.5mg Ateos
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →